Uncategorized
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
With fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on the chopping block.